![Page 1: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/1.jpg)
Presented by:-Jagohool SinghRoll no=1237MSc.Biotechnology 1stMDU ROHTAK
![Page 2: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/2.jpg)
An antibody is a protein used by the immune system to identify and neutralize foreign objects like bacteria and viruses. Each antibody recognizes a specific antigen unique to its target.
Monoclonal antibodies (mAb) are antibodies that are identical because they were produced by one type of immune cell, all clones of a single parent cell.
Polyclonal antibodies are antibodies that are derived from different cell lines.
![Page 3: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/3.jpg)
1975, Georges Köhler and Cesar Milstein- awarded Nobel Prize in1984
![Page 4: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/4.jpg)
In 1975, Kohler and Milstein first fused lymphocytes to produce a cell line which was both immortal and a producer of specific antibodies. The two scientists were awarded the Nobel Prize for Medicine in 1984 for the development of this "hybridoma." The value of hybridomas to the field was not truly appreciated until about 1987, when MAbs were regularly produced in rodents for diagnostics.
![Page 5: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/5.jpg)
PRODUCTION OF MONOCLONAL ANTIBODY
Step 1: - Immunization Of Mice & Selection Of Mouse Donor For Generation Of Hybridoma cells
HYBRIDOMA TECHNOLOGY
ANTIGEN ( Intact cell/ Whole cell membrane/ micro-organisms ) +
ADJUVANT (emulsification)
Ab titre reached in Serum
Spleen removed
(source of cells)
![Page 6: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/6.jpg)
PRODUCTION OF MONOCLONAL ANTIBODY
Step 2: - Preparation of Myeloma CellsHYBRIDOMA TECHNOLOGY
Myeloma CellsHGPRT-
(Hypoxanthin Guanine
phosphoribosyltransferase)
![Page 7: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/7.jpg)
PRODUCTION OF MONOCLONAL ANTIBODY
Step 3: - Fusion of Myeloma Cells with Immune Spleen Cells &
Selection of Hybridoma Cells
HYBRIDOMA TECHNOLOGY
FUSIONPEG
MYELOMA CELLSSPLEEN CELLS
HYBRIDOMA CELLSELISA PLATE
Feeder CellsGrowth Medium
HAT Medium
1. Plating of Cells in HAT selective Medium
2. Scanning of Viable Hybridomas
![Page 8: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/8.jpg)
![Page 9: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/9.jpg)
![Page 10: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/10.jpg)
![Page 11: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/11.jpg)
Selected by using HAT medium (Hypoxanthine-Aminopterin-Thymidine)
Myeloma cells are unable to grow B cells are able to survive, but can not live for
extended periods
![Page 12: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/12.jpg)
![Page 13: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/13.jpg)
(4) Fusion of myeloma and B cells (using PEG)(5) Separation of cell lines
![Page 14: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/14.jpg)
(6) Screening of suitable cell lines
![Page 15: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/15.jpg)
(7) in vitro (a) or in vivo (b) multiplication(8) Harvesting
![Page 16: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/16.jpg)
![Page 17: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/17.jpg)
Monoclonal antibodies are proving to be very useful as diagnostic, imaging, and therapuetic reagents in clinical medicine.
Many monoclonal antibody diagnostic reagents now available are products for detecting pregnancy, diagnosing numerous pathogenic microorganisms, measuring blood levels of various drugs, and detecting antigens shed by certain tumors.
![Page 18: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/18.jpg)
A pregnant woman has the hormone human chorionic gonadotrophin (HCG) in her urine.
Monoclonal antibodies to HCG have been produced. These have been attached to enzymes which can later interact with a dye molecule and produce a colour change.
![Page 19: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/19.jpg)
The test of HIV infection is based on detecting the presence of HIV antibody in the patient’s blood serum.
![Page 20: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/20.jpg)
a) HIV antigen is attached to the plate.b) Patients serum passed over the plate. Any
HIV antibody in the patients serum will attached to the antigen already on the plate.
c) A second antibody which is specific to the HIV antibody is passed over the plate. This antibody will attach to the concentrated HIV antibody on the plate. This second antibody has an enzyme attached to its structure.
d) Chromagen dye is passed over the complex of concentrated HIV antibody/conjugated antibody.
e) The enzyme will turn the chromagen to a more intense colour. The more intense the colour, the greater the HIV antibody level. This would be the a positive result for a HIV test.
![Page 21: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/21.jpg)
Cancer cells carry specific tumour-associated antigens (TAA) on their plasma membrane.
Monoclonal anti-TAA antibodies have been produced.
Drugs which kill tumour cells or inhibit key proteins in tumour cells are attached to monoclonal anti-TAA antibodies.
Cancer cells are specifically targeted, avoiding damage to healthy host cells.
![Page 22: Hybridoma technology and application for monoclonal antibodies](https://reader033.vdocument.in/reader033/viewer/2022052202/58787bad1a28ab466c8b50f5/html5/thumbnails/22.jpg)